



31 October 2022

ASX ANNOUNCEMENT

Change of Director's Interest Notice - Correction

ImpediMed Limited (ASX:IPD) (**Impedimed, Company**) refers to an earlier lodgement today of a Change of Director's Interest Notice for Mr Donald Williams. This notice inadvertently reported the opening balance of shares held incorrectly. The number of shares acquired on market and the balance now held were reported correctly.

The attached revised Change of Director's Interest Notice for Mr Williams reports the correct opening balance.

This announcement was approved for release by ImpediMed Limited's Company Secretary.

Contact Details

Investor relations Contact:

Mike Bassett, ImpediMed

T: +61 407 431 432

E: mbassett@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally.

For more information, visit www.impedimed.com.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: ImpediMed Limited
ABN: 089 705 144

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Donald Williams
Date of last notice	06 October 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	28 October 2022
No. of securities held prior to change	Direct – Don Williams 130,000 Ordinary shares Direct – Jointly Held 3,521,311 Ordinary shares
Class	Ordinary Shares
Number acquired	Direct – Jointly Held 1,707,825
Number disposed	Nil

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	1,487,825 at \$0.088 per share 220,000 at \$0.089 per share
No. of securities held after change	Direct – Don Williams 130,000 Ordinary shares Direct – Jointly Held 5,229,136 Ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On market trade.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

Date of Notice: 31 October 2022

⁺ See chapter 19 for defined terms.